Target intelligence / Profile preview

Pathogenic microorganism in gastrointestinal tract

Molecular classification
Other (microorganism; not a molecule or receptor), Bacteria (e.g., Clostridioides difficile, Salmonella enterica, Escherichia coli, Helicobacter pylori, Staphylococcus aureus), Viruses (e.g., norovirus, rotavirus), Fungi (e.g., Candida albicans), Archaea (e.g., Methanobrevibacter smithii), Protozoa (e.g., Giardia lamblia, Entamoeba histolytica)
01

Overview

Pathogenic microorganisms in the gastrointestinal tract collectively denote the diverse array of bacteria, viruses, fungi, archaea, and protozoa capable of causing disease in the digestive system. These agents can invade and colonize the gut, disrupt normal function, modulate the immune response, and produce toxins that contribute to varied GI symptoms and diseases, such as inflammation, infections, and sometimes cancer. Therapeutic approaches targeting these microbes focus on eliminating or reducing their populations (antibiotics, antifungals, antiparasitics, phage therapy), restoring microbial balance (probiotics, FMT), or selectively eradicating pathogenic strains while preserving beneficial ones. However, the term itself is not a specific molecular target but an umbrella category for a vast group of organisms and thus is not suitable as a canonical target for molecular drug development[1][2][5][6][7][8].

Other names
Gastrointestinal pathogenGI pathogensenteropathogensdigestive tract pathogens
02

Mechanism of action

Antibiosis (killing or inhibiting microbes); Disruption of microbial cell wall or membrane; Inhibition of microbial replication or metabolism; Selective targeting and lysis (bacteriophage therapy); Microbiome restoration (FMT, probiotics)

03

Biological functions

InfectionImmune response modulationDisruption of gut barrierProduction of toxinsInflammation
04

Disease associations

InfectionInflammationCancer (some species involved in colorectal cancer)Other (e.g., metabolic disorders, neurological symptoms mediated by the gut-brain axis)
05

Safety considerations

Antibiotic resistance (emerging with broad-spectrum antibiotics)Disruption of healthy microbiota ("dysbiosis") leading to secondary infections or other diseasesAllergic or immune reactions (e.g., with FMT, probiotics)Transmission of non-target pathogens in microbiome-based therapies (e.g., FMT, live biotherapeutics)
06

Interacting drugs

Antibiotics (e.g., vancomycin, metronidazole, rifaximin, ciprofloxacin)

5 more in the full profile.

07

Biomarkers

Microbial DNA/RNA (PCR detection for specific pathogens, e.g., C. difficile toxin genes)Microbial antigens (e.g., H. pylori antigen test)Host inflammatory markers (e.g., calprotectin, C-reactive protein)Microbiome diversity indices (for efficacy monitoring in FMT)

Beyond the preview

Go deeper on Pathogenic microorganism in gastrointestinal tract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pathogenic microorganism in gastrointestinal tract.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call